BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10448019)

  • 1. Metabolic treatment of myocardial ischaemia.
    Ferrari R
    Eur Heart J; 1999 Aug; 20(16):1144-5. PubMed ID: 10448019
    [No Abstract]   [Full Text] [Related]  

  • 2. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
    Labrid C
    Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Trimetazidine (Preductal). A new approach in controlling myocardial ischemia].
    Eliseev OM
    Ter Arkh; 1996; 68(8):57-63. PubMed ID: 9019836
    [No Abstract]   [Full Text] [Related]  

  • 4. [Myocardial cytoprotection with trimetazidine in patients with ischemic heart disease during surgical stress].
    Afanas'eva IV; Goncharova LL; Miroshnichenko AG; Petrash VV; Pokrovskaia LA
    Vestn Khir Im I I Grek; 1999; 158(5):34-7. PubMed ID: 10645577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
    O'Meara E; McMurray JJ
    Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological preconditioning as a way of the increasing of myocytes resistance to ischemia].
    Wilczewski P; Poloński L
    Wiad Lek; 2000; 53(7-8):449-53. PubMed ID: 11070768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enhancement of antioxidant status of the elderly patients with ischemic heart disease in response to amino acid composition of MP-33 in combined therapy with trimetazidine].
    Kalinina EB; Komissarova IA; Zaslavskaia RM; Zhdanov IuA
    Klin Med (Mosk); 2002; 80(5):50-3. PubMed ID: 12087889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can metabolic manipulation reverse myocardial dysfunction?
    Cokkinos DV
    Eur Heart J; 2001 Dec; 22(23):2138-9. PubMed ID: 11913472
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
    Rizzon P; Iliceto S; Marangelli V
    Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic therapy for heart failure.
    Essop MF; Opie LH
    Eur Heart J; 2004 Oct; 25(20):1765-8. PubMed ID: 15474689
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic application of myocardial cytoprotection].
    Ribeiro C
    Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
    Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
    Stanley WC; Sabbah HN
    Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia.
    Khazanov VA; Kiseliova AA; Vasiliev KY; Chernyschova GA
    Bull Exp Biol Med; 2008 Aug; 146(2):218-22. PubMed ID: 19145322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC; Marzilli M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic therapy for the diabetic patients with ischaemic heart disease.
    Rosano GM; Vitale C; Volterrani M; Fini M
    Coron Artery Dis; 2005 Nov; 16 Suppl 1():S17-21. PubMed ID: 16340399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
    Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
    Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angina, myocardial hibernation and trimetazidine.
    Jackson G
    Int J Clin Pract; 1997 Sep; 51(6):347. PubMed ID: 9489058
    [No Abstract]   [Full Text] [Related]  

  • 20. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
    Monteiro P; Duarte AI; Gonçalves LM; Moreno A; Providência LA
    Eur J Pharmacol; 2004 Oct; 503(1-3):123-8. PubMed ID: 15496306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.